GT Biopharma, Inc (GTBP)
| Market Cap | 39.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 90.95M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $0.4700 |
| Previous Close | $0.4600 |
| Change ($) | 0.0100 |
| Change (%) | 2.17% |
| Day's Open | 0.4850 |
| Day's Range | 0.4500 - 0.4850 |
| Day's Volume | 544,799 |
| 52-Week Range | 0.083 - 0.77 |
BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...
BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...
BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK ...
BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK ce...
BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK...
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...
GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.
About GTBP
GT Biopharma, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase... [Read more...]
| Industry Biotechnology | Founded 1965 |
| CEO Anthony Cataldo | Employees 2 |
| Stock Exchange OTCMKTS | Ticker Symbol GTBP |